1. Sekhri R, Ortanca I, Boals C, Agarwal S. Salivary duct carcinoma: A case report of oncocytic variant with possible treatment implications and review of literature. Pathol Res Pract. 2019 Oct;215(10):152549. doi: 10.1016/j.prp.2019.152549.
  2. Xu B, Dogan S, Haroon Al Rasheed MR, Ghossein R, Katabi N. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance. Hum Pathol. 2019 Nov; 93:30-36. doi: 10.1016/j.humpath.2019.08.007.
  3. Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer. 2001 Oct 25;93(5):344-50. doi: 10.1002/cncr.9050. PMID: 11668470.
  4. Liang, L., Williams, M.D. & Bell, D. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma. Head and Neck Pathol. 2019; 13, 529–534.
  5. Chiosea, Simion I. MD; Williams, Lindsay MD; Griffith, Christopher C. MD, PhD; Thompson, Lester D.R. MD; Weinreb, Ilan MD; Bauman, Julie E. MD et al. Molecular Characterization of Apocrine Salivary Duct Carcinoma. Am J Surg Pathol. 2015 Jun; 39 (6),744-752. doi: 10.1097/PAS.0000000000000410.
  6. Chiosea, S.I., Thompson, L.D.R., Weinreb, I., Bauman, J.E., Mahaffey, A.M., Miller, C., et al. Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations. Cancer. 2016; 122: 3136-3144.
  7. Giordano, G., Gabrielli, M., Gnetti, L. et al. Oncocytic carcinoma of parotid gland: a case report with clinical, immunohistochemical and ultrastructural features. World J Surg Onc. 2006; 4, 54.
  8. Catalina Acevedo, Claudia Amaya, Jose-Luis López-Guerra. Rare breast tumors: Review of the literature. Reports of Practical Oncology & Radiotherapy. 2014; 19 (4), 267-274,